tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kemp Dolliver, 9 are a BUY (75%), 3 are a HOLD (25%).
Analyst Kemp Dolliver, currently employed at BROOKLINE, carries an average stock price target met ratio of 38.89% that have a potential upside of 18.14% achieved within 37 days.
Kemp Dolliver’s has documented 22 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on YMAB, Y mAbs Therapeutics at 03-Mar-2025.
Analyst best performing recommendations are on VRCA (VERRICA PHARMACEUTICALS).
The best stock recommendation documented was for VRCA (VERRICA PHARMACEUTICALS) at 3/9/2022. The price target of $20 was fulfilled within 78 days with a profit of $59.6 (74.87%) receiving and performance score of 9.6.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$25
$20.09 (409.16%)
$25
7 months 6 days ago
(13-Mar-2025)
6/9 (66.67%)
$15.45 (161.78%)
421
Buy
$1.25
$-5.56 (-81.64%)
2 years 9 months 7 days ago
(13-Jan-2023)
0/1 (0%)
$-3.28 (-72.41%)
What Year was the first public recommendation made by Kemp Dolliver?
